Kodiak Sciences Announces Completion Of 300-Patient Enrollment In First Pivotal Cohort Of Phase 3 PEAK Trial For KSI-101; Says Topline Data On Track For December 2026

Benzinga Newsdesk www.benzinga.com Positive 82.3%

Neg 0% Neu 0% Pos 82.3%

Comments

No comments yet. Be the first!